ArticleThe Journal of dermatology2025
Prevalence and incidence of comorbidities in patients with atopic dermatitis, psoriasis, alopecia areata, and vitiligo using a Japanese claims database.
Article in The Journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.American journal of clinical dermatology · 2026Trial
- Elevated Risk of Herpes Zoster in Vitiligo Patients: A Nationwide Population-Based Cohort Study of Taiwan.The Journal of dermatology · 2026Article
- Article
- Health-Related Quality of Life and Psychological Burden of Patients With Vitiligo in Japan.The Journal of dermatology · 2026Article
- Cardiovascular risk among middle-aged Japanese adults with atopic dermatitis: A nested case-control study.PloS one · 2026Article
- Burden, Trends, Associated Diseases and Predictions of Alopecia Areata in China, Japan, South Korea, and Globally: A GBD 2023 Analysis.Clinical, cosmetic and investigational dermatology · 2026Article
- Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review.Dermatology and therapy · 2025Review
- Ophthalmologic Comorbidities in Alopecia Areata.Journal of clinical medicine · 2025Review
- Exploring the Association Between Multidimensional Dietary Patterns and Non-Scarring Hair Loss Using Mendelian Randomization.Nutrients · 2025Article
- Article
- Prevalence and incidence of comorbidities in patients with atopic dermatitis, psoriasis, alopecia areata, and vitiligo using a Japanese claims database.The Journal of dermatology · 2025Article
- Antimicrobial and Anti-Infective Potential of Herbal Creams in Dermatology: Efficacy, Safety, and Challenges in Skin Infection Management.Infection and drug resistance · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Atopic dermatitis, psoriasis, alopecia areata, and vitiligo have been associated with comorbid conditions, including infections, malignancies, and cardiovascular diseases. This study evaluated the prevalence and incidence rates of these comorbidities in patients from Japan. This retrospective cohort study used data collected from the JMDC claims database between June 2013 and December 2020. Patients with a diagnosis of atopic dermatitis, psoriasis, alopecia areata, or vitiligo were matched (1:1) by age, sex, and index month with individuals with no claims records for atopic dermatitis, psoriasis, alopecia areata, or vitiligo diagnosis. Data included 691 338, 51 988, 43 692, and 8912 patients in the atopic dermatitis, psoriasis, alopecia areata, and vitiligo cohorts, respectively, and matched controls. The most prevalent comorbidities in the atopic dermatitis cohort versus matched controls included allergic rhinitis (47% vs 37%), conjunctivitis (33% vs 23%), asthma (27% vs 20%), viral infection (22% vs 15%), and acne (11% vs 3%). Incidence rates per 100 000 person-years of comorbidities in the atopic dermatitis cohort versus matched controls were: venous thromboembolism, 51.4 (95% confidence interval [CI], 48.3-54.7) versus 31.7 (95% CI, 29.2-34.2); lymphoma, 13.8 (95% CI,12.2-15.6) versus 5.7 (95% CI, 4.7-6.8); cutaneous T-cell lymphoma, 1.6 (95% CI, 1.1-2.2) versus 0.1 (95% CI, 0.0-0.4); and herpes zoster, 740.9 (95% CI, 728.8-753.1) versus 397.6 (95% CI, 388.9-406.6). Similar trends were observed in the psoriasis versus nonpsoriasis cohorts, with 95% CIs mostly overlapping for alopecia areata and vitiligo cohorts versus controls. Overall, patients from Japan with dermatologic diseases have a higher prevalence and incidence of certain health conditions, particularly venous thromboembolism, lymphoma, and infections in patients with atopic dermatitis and psoriasis, compared with individuals without these dermatologic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.